Storage protective agent, storage method and detection method of biological sample

By adding storage protectant of inorganic salt solution to biological samples and using low-temperature storage and LC-MS/MS detection methods, the problems of sample storage time and detection efficiency are solved, and the stability and efficient detection of the samples are achieved.

CN119032930APending Publication Date: 2024-11-29SHANGHAI CELL THERAPY GROUP CO LTD
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410169254.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-02-06
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing detection methods require a large amount of fresh blood, are cumbersome to operate, and cannot be stored at low temperatures and transported remotely, resulting in a decrease in NAD+/NADH content, unable to extend the sample storage time and optimize detection methods.

Method used

The storage protectant containing inorganic salt solution was added to the biological sample, and was detected by low-temperature storage method (≤-80°C) and high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS). The internal standard was β- NMN-d4 and β-NAD-13C5, samples can be frozen and thawed multiple times without affecting the results.

Benefits of technology

The sample storage time is extended to more than 7 days, the blood consumption is reduced, the detection process is simplified, and the simultaneous detection of NMN/NAD+ is realized, which supports actual sample detection, and the metabolites in the sample are good.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004700564520000011
    Figure HDA0004700564520000011
  • Figure HDA0004700564520000012
    Figure HDA0004700564520000012
  • Figure HDA0004700564520000021
    Figure HDA0004700564520000021
Patent Text Reader

Abstract

The invention belongs to the field of biological sample preservation, and relates to a biological sample storage protective agent, a storage method and a detection method, the storage protective agent at least contains an inorganic salt solution, and can maintain the stability of various metabolic small molecules in blood and / or cells; the kit is used for storing blood samples and / or cell samples after taking NAD or precursor molecule anti-aging components thereof, and is convenient for effect evaluation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of low-temperature preservation and relates to a storage protective agent, a storage method and a detection method for a biological sample. Background Art

[0002] The immune system changes with age. After the age of 40, the body's immune cells begin to age significantly, which reduces the ability to fight viruses and bacteria, and increases the risk of infection, chronic diseases and cancer. NAD+ (nicotinamide adenine dinucleotide, referred to as coenzyme I) is a coenzyme for many dehydrogenases in the body, connecting the tricarboxylic acid cycle and the respiratory chain. Its function is to transfer hydrogen removed during metabolism to flavin proteins. NAD+ can provide cell energy supply and promote cell regeneration. The metabolism of NAD+ in cells is as follows: Figure 1 shown.

[0003] Taking NAD or its precursor molecules can help delay aging. In order to provide feedback on the absorption of NAD or its precursor molecules by the population and the NAD+ / NADH conversion rate, and to facilitate the assessment of the aging state, it is necessary to monitor the NMN and NAD+ / NADH levels in the body in real time. The current detection method mainly collects whole blood samples from the subjects, extracts PBMCs, and then detects them using an ELISA test kit. This method uses a large amount of blood and requires the extraction of PBMCs. The operation is cumbersome and the workload is large. In addition, the blood and PBMCs must be kept fresh, cannot be frozen, and cannot be transported over long distances. After obtaining the sample, it must be measured as soon as possible, otherwise the NAD+ / NADH content will drop significantly. How to extend the storage time of the sample to be tested and optimize the detection methods at the same time are still technical problems that need to be solved in this field. Summary of the invention

[0004] The purpose of the present invention is to provide a storage protectant for biological samples, which can stabilize the metabolites in the samples and realize low-temperature transportation.

[0005] The specific technical solutions are as follows:

[0006] A storage protective agent for a biological sample, the storage protective agent at least containing an inorganic salt solution.

[0007] In some embodiments, the inorganic salt solution is a saturated inorganic salt. In some embodiments, the inorganic salt is selected from any one or more of ammonium sulfate, sodium sulfate, sodium chloride, and ammonium chloride, preferably ammonium sulfate.

[0008] In some specific embodiments, the volume ratio of the storage protectant to the biological sample is ≥3:1.

[0009] In some embodiments, the biological sample contains a metabolic small molecule, preferably NAD or a precursor molecule thereof, and the NAD+ precursor is selected from one or more of tryptophan, quinolinic acid, nicotinic acid (NA), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), or a food or pharmaceutically acceptable salt, derivative or prodrug thereof, preferably nicotinamide mononucleotide (NMN).

[0010] In some embodiments, the biological sample is a blood sample and / or a cell sample, wherein the blood sample is a whole blood sample.

[0011] The present invention also provides a method for storing biological samples, wherein the storage method uses the storage protective agent as described above.

[0012] In some embodiments, the storage method is low-temperature storage, and the low temperature is ≤0°C, preferably ≤-20°C, more preferably ≤-78°C, and even more preferably ≤-80°C.

[0013] The present invention also provides a method for detecting metabolic small molecules in a biological sample, wherein the biological sample is stored using the storage method described above.

[0014] In some embodiments, the metabolic small molecule is NAD or a precursor molecule thereof, and the NAD+ precursor is selected from one or more of tryptophan, quinolinic acid, nicotinic acid (NA), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), or alimentarily or pharmaceutically acceptable salts, derivatives or prodrugs thereof; preferably nicotinamide mononucleotide (NMN).

[0015] In some embodiments, the detection method has any one or more of the following features:

[0016] 1) The detection method is high performance liquid chromatography tandem mass spectrometry (LC-MS / MS);

[0017] 2) The LC-MS / MS method contains an internal standard, which is an isotope-labeled internal standard of the molecule to be tested, preferably β-NMN-d4 and β-NAD- 13 C5;

[0018] 3) The biological sample is a blood sample and / or a cell sample, wherein the blood sample is a whole blood sample;

[0019] 4) The biological sample has been frozen at least once. Failure to freeze and thaw will result in incomplete cell lysis and low NAD+ concentration.

[0020] The beneficial effects of the present invention are:

[0021] By adding storage protectants to biological samples, the metabolites are stabilized and low-temperature transportation is achieved, which can extend the storage time to more than 7 days, up to about 3 months. After the frozen biological samples are thawed, the storage protectants can protect the metabolites in the samples from decomposition, and the storage time is greater than 24 hours, which is conducive to actual sample testing.

[0022] The use of LC-MS / MS to replace the original ELISA method overcomes the problem of requiring a large amount of fresh blood to extract PBMC, and reduces the amount of blood used. At the same time, LC-MS / MS can be automated for detection, which is simple, convenient, and requires little workload.

[0023] The simultaneous detection of NMN / NAD+ is achieved, which helps to objectively reflect the real-time effects after subjects take NAD or its precursor molecules. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] Figure 1 A schematic diagram showing the metabolism of NAD+ in cells;

[0025] Figure 2 The comparison of NAD+ concentration in whole blood, plasma, and blood cells is shown;

[0026] Figure 3 It shows that NAD+ is completely decomposed after freezing and thawing for 30 minutes without adding storage protectant;

[0027] Figure 4 It was shown that the addition of storage protectants did not affect the determination of NAD+ content;

[0028] Figure 5 It shows that storage at 4°C has a significant impact on the detection of metabolic small molecules in samples;

[0029] Figure 6 The short-term preservation effect of the samples after adding storage protectants is shown;

[0030] Figure 7 The long-term preservation effect of the samples after adding storage protectants is shown;

[0031] Figure 8 It was shown that the samples could withstand multiple freeze-thaw cycles after adding storage protectants;

[0032] Fig. 9 Shown are the results of stability testing of whole blood samples after pretreatment. DETAILED DESCRIPTION

[0033] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0034] One of the purposes of the present invention is to provide a storage protective agent for biological samples, wherein the storage protective agent contains at least an inorganic salt solution, preferably a saturated inorganic salt solution.

[0035] In some embodiments, the saturated inorganic salt is selected from any one or more of saturated ammonium sulfate, saturated sodium sulfate, saturated sodium chloride, and saturated ammonium chloride, preferably saturated ammonium sulfate.

[0036] The term "saturated inorganic salt solution" refers to the solution obtained when an inorganic salt can no longer dissolve in a certain amount of pure water.

[0037] In some specific embodiments, the volume ratio of the storage protectant to the biological sample is ≥3:1, for example, the volume ratio of the storage protectant to the biological sample is 3:1, 4:1, 5:1, etc.

[0038] The storage protective agent may be added before the biological sample is frozen, or the frozen biological sample may be added to the storage protective agent for thawing.

[0039] In some embodiments, the biological sample contains metabolic small molecules, preferably NAD or a precursor molecule thereof.

[0040] The term "NAD+ precursor" is any small molecule that results in an increase in NAD+, and the small molecule can exist in reduced or non-reduced form.

[0041] NAD+ is a cofactor that plays a core role in metabolism, and NAD+ levels decrease with age. NAD+ can help repair DNA, regulate immune cell conduction, provide cell energy and reduce aging. During the in vitro preparation of immune cells, adding NAD+ treatment can provide sufficient energy for immune cell expansion, improve immune cell expansion and reduce cell aging indicators. NAD+ precursors are compounds that are converted into NAD+ through chemical conversion.

[0042] In some embodiments, the NAD+ precursor is selected from one or more of tryptophan, quinolinic acid, nicotinic acid (NA), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), or a food or pharmaceutically acceptable salt, derivative or prodrug thereof; preferably nicotinamide mononucleotide (NMN). As a direct precursor of NAD+, NMN can be easily directly converted into NAD+ by NMNAT enzyme and easily absorbed by cells.

[0043] In some embodiments, the biological sample is a blood sample and / or a cell sample, wherein the blood sample is a whole blood sample, and the cell sample is a human cell, including nerve cells, white blood cells, red blood cells, platelets, macrophages, epithelial cells, cardiomyocytes, stem cells, etc. For example, PBMC can be used.

[0044] The term "whole blood" refers to the mixture formed by collecting blood from the human body into a blood collection bag, which includes all components of blood cells and plasma.

[0045] The term "PBMC" stands for peripheral blood mononuclear cells (PBMC), which are cells with a single nucleus in peripheral blood, including lymphocytes and monocytes.

[0046] A second object of the present invention is to provide a method for storing biological samples, wherein the storage method uses the storage protective agent as described above.

[0047] In some embodiments, the storage method is low temperature storage, and the low temperature is ≤0°C, preferably ≤-20°C, more preferably ≤-78°C, and even more preferably ≤-80°C. That is, the low temperature can be sufficient to freeze the biological sample, for example, ≤0°C, ≤-5°C, ≤-10°C, ≤-15°C, ≤-20°C, ≤-30°C, ≤-40°C, ≤-50°C, ≤-60°C, ≤-70°C, ≤-78°C (can be stored by dry ice), ≤-80°C (can be stored at -80°C).

[0048] The term "dry ice storage" refers to storing samples in a foam box or insulated box filled with dry ice.

[0049] The term "-80°C storage" means that the samples were stored in a -80°C freezer.

[0050] A third object of the present invention is to provide a method for detecting metabolic small molecules in a biological sample, wherein the biological sample is stored using the storage method described above.

[0051] In some embodiments, the metabolic small molecule is NAD or a precursor molecule thereof, and the NAD+ precursor is selected from one or more of tryptophan, quinolinic acid, nicotinic acid (NA), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), or alimentarily or pharmaceutically acceptable salts, derivatives or prodrugs thereof; preferably nicotinamide mononucleotide (NMN).

[0052] In some embodiments, the detection method is high performance liquid chromatography tandem mass spectrometry (LC-MS / MS method). High performance liquid chromatography-tandem mass spectrometry technology uses a liquid chromatography system to separate the substance to be tested and then connects it to a mass spectrometer. The substance to be tested is ionized and converted into an electrical signal. After computer data processing, it is analyzed according to the mass spectrum peak. It has the excellent separation ability of liquid chromatography and the high sensitivity and high selectivity of mass spectrometry.

[0053] The LC-MS / MS method contains an internal standard, which is an isotope-labeled internal standard of the molecule to be measured.

[0054] In some specific embodiments, the internal standard is preferably β-NMN-d4 and β-NAD-13C5;

[0055] In some embodiments, the biological sample is a blood sample and / or a cell sample, wherein the blood sample is a whole blood sample.

[0056] In some embodiments, the biological sample is frozen at least once, that is, the biological sample is frozen to completely lyse the cells, and then tested after thawing, and the number of freeze-thaw cycles can be 1, 2, 3, 4, 5, etc.

[0057] The present invention will be described below in the form of specific examples. It should be understood that these examples are merely illustrative and are not intended to limit the scope of the present invention. The methods and materials used in the examples are, unless otherwise stated, materials and methods conventional in the art.

[0058] Example 1 Comparison of NAD+ concentrations in whole blood, plasma, and whole blood cells

[0059] The collected whole blood sample is subjected to plasma separation to obtain plasma and blood cells.

[0060] Add 850 μL of saturated ammonium sulfate solution and 50 μL of fresh sample to be tested (divided into 3 groups, namely whole blood / plasma / blood cells) to a 1.5 mL centrifuge tube, shake evenly, and freeze the EP tube in liquid nitrogen for 2 minutes;

[0061] Take out the frozen EP tube and place it in an ice box to thaw. After thawing, add 50 μL of internal standard solution (containing β-NMN-d4, β-NAD- 13 C5), shake evenly; put the EP tube into an ice water bath for ultrasonication for 10 minutes; immediately after ultrasonication, put the EP tube into a centrifuge and centrifuge at 10000 rpm for 3 minutes; take the supernatant after centrifugation and filter it into a sample bottle, and use LC-MS / MS method for quantitative detection.

[0062] After testing whole blood, plasma, and blood cells, it was found that ( Figure 2 ), plasma contains almost no NMN / NAD+, and the results of whole blood and blood cell tests are basically the same. Therefore, the following experiments all use whole blood samples for NMN / NAD+ detection.

[0063] Example 2 Screening of storage and pretreatment methods for whole blood samples

[0064] Pretreatment method 1: Freeze the collected samples in liquid nitrogen for 2 minutes, and immediately add 850 μL of saturated ammonium sulfate solution and 50 μL of internal standard solution (containing β-NMN-d4, β-NAD- 13 C5), mixing, ultrasonication, centrifugal filtration, and then sampling and analyzing the NMN / NAD+ concentration;

[0065] Pretreatment method 2: The collected samples were frozen in liquid nitrogen for 2 minutes, and after thawing, they were divided into groups and placed in a room temperature and 4°C refrigerator for 30 minutes each, and then 850 μL of saturated ammonium sulfate solution and 50 μL of internal standard solution (containing β-NMN-d4, β-NAD- 13 C5), mixing, ultrasonication, centrifugal filtration, and then sampling and analyzing the NMN / NAD+ concentration;

[0066] Pretreatment method 3: Add 850 μL of saturated ammonium sulfate solution and 50 μL of internal standard solution (containing β-NMN-d4, β-NAD- 13 C5) Mix well, freeze in liquid nitrogen for 2 minutes, place at room temperature for 30 minutes after thawing, mix well, sonicate, centrifuge and filter, then sample and analyze NMN / NAD+ concentration;

[0067] Experiment 1 (pretreatment method 1 and pretreatment method 2): Comparison of the test results of samples without storage protectant added before freezing, immediately after freezing and thawing, and after 30 minutes of storage, showed that NAD+ was completely decomposed at room temperature and 4°C for 30 minutes ( Figure 3 ).

[0068] Experiment 2 (Pretreatment Method 1 and Pretreatment Method 3): Comparison of samples without storage protectant and samples with storage protectant before freezing. The results showed that freezing did not affect the determination of NAD+ content ( Figure 4 ), saturated ammonium sulfate can maintain the stability of various metabolic small molecules in the blood.

[0069] Experiment 3 (Pretreatment Method 1 and Pretreatment Method 3): Comparison of the changes in NAD+ concentration in whole blood samples at different storage times at 4°C. The results show ( Figure 5 ), regardless of whether a storage protectant is added, the content of NAD+ changes irregularly over time. Among them, the content of NAD+ shows an upward trend over time. The possible reason is that NMN will continue to convert to NAD+ under 4°C conditions, and the NAD+ consumption pathway in the blood will decrease after leaving the human body, resulting in the synthesis rate of NAD+ being greater than the consumption rate. Therefore, cryopreservation of biological samples is a necessary condition to ensure the detection of NAD+ concentration.

[0070] Example 3 Verification of the storage effect of cryoprotectants

[0071] In the following experiments, storage protectants were added before freezing the biological samples:

[0072] 3.1 Short-term cryopreservation: Add 4 times the volume of saturated ammonium sulfate solution to the collected samples, mix them well, store them on dry ice and at -80 °C, melt them at 0 h, 24 h, and 48 h, take samples, add internal standard solution (containing β-NMN-d4, β-NAD- 13 C5), mixing, ultrasonication, centrifugal filtration, and then sampling and analyzing the NMN / NAD+ concentration to detect the change of NMN / NAD+ concentration over time. The results show that Figure 6 The storage protective agent can ensure that the whole blood sample is stable when stored in dry ice for 48 hours, and the blood samples from other provinces and cities can be delivered for testing. The storage protective agent can ensure that the whole blood sample is stable when stored at -80℃ for 48 hours, and the samples can be stored locally.

[0073] 3.2 Long-term cryopreservation: Add 4 times the volume of saturated ammonium sulfate solution to the collected samples, store them at -80℃ and -20℃, melt them and take samples at 0 days, 1 day, 2 days, 3 days and 7 days, add internal standard solution (containing β-NMN-d4, β-NAD- 13 C5), mixing, ultrasonication, centrifugal filtration, and then sampling and analyzing the NMN / NAD+ concentration to detect the change of NMN / NAD+ concentration over time. The results show that Figure 7 After using storage protectants and freezing, the NMN / NAD+ in the blood sample can be guaranteed to change less than 8% within 7 days, and the method stability is excellent.

[0074] 3.3 Freeze-thaw cycles: The collected samples were added with 4 times the volume of saturated ammonium sulfate solution, and repeatedly frozen at -80 °C and thawed at room temperature within 24 h. Samples were taken after 0, 1, 3, and 5 freeze-thaw cycles, and internal standard solution (containing β-NMN-d4, β-NAD- 13 C5), after mixing, ultrasonication, centrifugal filtration, and analysis of NMN / NAD+ concentration, the results showed that Figure 8 Blood samples treated with storage protectants can withstand multiple freeze-thaw cycles and will not affect the NMN / NAD+ detection results in the blood samples. However, they must be frozen. Direct storage at 4°C (direct testing without freeze-thaw) will result in incomplete cell lysis and low NAD+ concentration.

[0075] 3.4 Stability test of whole blood samples after pretreatment: Add 4 times the volume of saturated ammonium sulfate solution to the sample to be tested, freeze at -80°C, thaw at room temperature, and add internal standard solution (containing β-NMN-d4, β-NAD- 13 C5), mixed, ultrasonicated, centrifuged and filtered, the test solution was stored in a sample chamber at 10°C for 24 hours. Fig. 9The NMN / NAD+ concentration in the sample remains unchanged and has not deteriorated, which can ensure that when a large number of samples are tested, the test results will not be affected by the long detection time.

[0076] In summary, ① biological samples containing storage protectants can be stored for more than 7 days, meeting the needs of long-distance transportation of samples; ② biological samples containing storage protectants can undergo multiple freeze-thaw cycles without affecting the experimental results; ③ biological samples containing storage protectants can be stored for more than 24 hours after freezing and thawing, meeting the actual needs of sample testing.

Claims

1. A storage protective agent for biological samples, characterized in that: The storage protective agent at least contains an inorganic salt solution.

2. The storage protective agent according to claim 1, characterized in that: The inorganic salt solution is a saturated inorganic salt solution.

3. The storage protective agent according to claim 1 or 2, characterized in that: The inorganic salt is selected from any one or more of ammonium sulfate, sodium sulfate, sodium chloride, and ammonium chloride, preferably ammonium sulfate.

4. The storage protective agent according to any one of claims 1 to 3, characterized in that: The volume ratio of the storage protectant to the biological sample is ≥3:

1.

5. The storage protective agent according to any one of claims 1 to 4, characterized in that: The biological sample contains metabolic small molecules, preferably NAD or its precursor molecule, and the NAD+ precursor is selected from tryptophan, quinolinic acid, nicotinic acid (NA), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), or one or more of their food or pharmaceutically acceptable salts, derivatives or prodrugs, and is further preferably nicotinamide mononucleotide (NMN).

6. The storage protective agent according to any one of claims 1 to 5, characterized in that: The biological sample is a blood sample and / or a cell sample, wherein the blood sample is a whole blood sample.

7. A method for storing biological samples, characterized in that: The storage method uses the storage protective agent as described in any one of claims 1 to 6.

8. The storage method according to claim 7, characterized in that: The storage method is low-temperature storage, and the low temperature is ≤0°C, preferably ≤-20°C, more preferably ≤-78°C, and even more preferably ≤-80°C.

9. A method for detecting metabolic small molecules in a biological sample, characterized in that: The biological sample is stored using the storage method as described in claim 7 or 8.

10. The detection method according to claim 9, characterized in that: The metabolic small molecule is NAD or its precursor molecule, and the NAD+ precursor is selected from one or more of tryptophan, quinolinic acid, nicotinic acid (NA), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), or a food or pharmaceutically acceptable salt, derivative or prodrug thereof; preferably nicotinamide mononucleotide (NMN).

11. The detection method according to claim 9 or 10, characterized in that: The detection method has any one or more of the following characteristics: 1) The detection method is high performance liquid chromatography tandem mass spectrometry (LC-MS / MS); 2) The LC-MS / MS method contains an internal standard, which is an isotope-labeled internal standard of the molecule to be tested, preferably β-NMN-d4 and β-NAD- 13 C5; 3) The biological sample is a blood sample and / or a cell sample, wherein the blood sample is a whole blood sample; 4) The biological sample has been frozen at least once.

Citation Information

Cited By

  • Storage protective agent, collection card, and storage and detection method for biological sample

    WO2025167593A1